Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Dow
Cerilliant
Baxter
McKinsey
Cipla
Teva
Merck
Healthtrust
US Department of Justice

Generated: April 23, 2018

DrugPatentWatch Database Preview

Details for Patent: 8,734,845

« Back to Dashboard

Which drugs does patent 8,734,845 protect, and when does it expire?

Patent 8,734,845 protects AFREZZA and is included in one NDA.

This patent has twenty-one patent family members in fifteen countries.
Summary for Patent: 8,734,845
Title:Diketopiperazine microparticles with defined specific surface areas
Abstract: Disclosed herein are diketopiperazine microparticles having a specific surface area of less than about 67 m.sup.2/g. The diketopiperazine microparticle can be fumaryl diketopiperazine and can comprise a drug such as insulin.
Inventor(s): Grant; Marshall L. (Newtown, CT), Stowell; Grayson W. (Gaylordsville, CT), Menkin; Paul (Branford, CT)
Assignee: Mannkind Corporation (Valencia, CA)
Application Number:13/377,682
Patent Claim Types:
see list of patent claims

Drugs Protected by US Patent 8,734,845

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Mannkind AFREZZA insulin recombinant human POWDER;INHALATION 022472-001 Jun 27, 2014 RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Mannkind AFREZZA insulin recombinant human POWDER;INHALATION 022472-002 Jun 27, 2014 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Mannkind AFREZZA insulin recombinant human POWDER;INHALATION 022472-003 Apr 17, 2015 RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 8,734,845

PCT Information
PCT FiledJune 11, 2010PCT Application Number:PCT/US2010/038298
PCT Publication Date:December 16, 2010PCT Publication Number: WO2010/144789

Non-Orange Book US Patents Family Members for Patent 8,734,845

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,630,930 Diketopiperazine microparticles with defined specific surface areas ➤ Try a Free Trial
8,551,528 Diketopiperazine microparticles with defined specific surface areas ➤ Try a Free Trial
8,778,403 Diketopiperazine microparticles with defined specific surface areas ➤ Try a Free Trial
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 8,734,845

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 077086 ➤ Try a Free Trial
Australia 2010259943 ➤ Try a Free Trial
Brazil PI1013154 ➤ Try a Free Trial
Canada 2764505 ➤ Try a Free Trial
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Argus Health
Accenture
Cipla
Fish and Richardson
Chinese Patent Office
Colorcon
Dow
Farmers Insurance
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.